Biblio
Impact of Cyclosporine-A Concentration on Acute Graft-versus-Host Disease Incidence after Haploidentical Hematopoietic Cell Transplantation. Eur J Haematol. 2019.
Infectious complications after post-transplantation cyclophosphamide and anti-thymocyte globulin-based haploidentical stem cell transplantation. Br J Haematol. 2019.
Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation. Eur J Cancer. 2019;115:47-56.
CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. Bone Marrow Transplant. 2020.
Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma. Blood Adv. 2020;4(7):1242-1249.
COVID-19 in the context of autologous hematopoietic stem cell transplantation for a patient with autoimmune disease. Curr Res Transl Med. 2021;70(2):103332.
COVID-19 and Hairy-Cell Leukemia: An EPICOVIDEHA Survey. Blood Adv. 2022.
Immune restoration therapy for multidrug-resistant CMV disease in an allogenic stem cell transplant recipient. Curr Res Transl Med. 2022;70(2):103329.
Axicabtagene ciloleucel in large B cell lymphoma ineligible for autologous stem cell transplantation: the phase 2 ALYCANTE trial. Nat Med. 2023.
Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transplant. 2023.
Active infection at the time of CD34+ selected stem cell boost is associated with treatment failure and poor survival. Blood Adv. 2024.
Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives. Blood Cancer J. 2024;14(1):23.
. Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022. EClinicalMedicine. 2024;71:102553.